Skip to main content

Table 2 Characterization of nanoparticles

From: A ROS-responsive polymeric prodrug nanosystem with self-amplified drug release for PSMA (−) prostate cancer specific therapy

Nanoparticles

Size (nm)

PDI

Zeta (mV)

DLC of DOX (%)

DLC of α-TOS (%)

DEE of α-TOS (%)

ATD-NPs

141

0.27

− 27.2

19.7

9.4

91.2

TD-NPs

106

0.23

− 13.5

20.8

9.8

93.5

AD-NPs

125

0.28

− 24.7

22.4